Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: Part II

Clinical Pharmacokinetics

Volumn 48, Issue 8, 2009, Pages 489-516

  Monchaud, Caroline ^a   Marquet, Pierre ^a,b  

^a UNIVERSITY OF LIMOGES   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; HEART LUNG TRANSPLANTATION; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LUNG TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; THORAX SURGERY;

ANIMALS; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; THORACIC SURGICAL PROCEDURES; TISSUE DISTRIBUTION;

EID: 69249136223     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11317240-000000000-00000     Document Type: Review

References (152)

1. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007; 46 (1): 13-58
2. Ensom MH, Partovi N, Decarie D, et al. Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. Ther Drug Monit 2002 Apr; 24 (2): 310-4
3. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006 Apr; 28 (2): 145-54
4. Baraldo M, Isola M, Feruglio MT, et al. Therapeutic mycophenolic acid monitoring by means of limited sampling strategy in orthotopic heart transplant patients. Transplant Proc 2005 Jun; 37 (5): 2240-3
5. Armstrong VW, Tenderich G, Shipkova M, et al. Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. Ther Drug Monit 2005 Jun; 27 (3): 315-21
6. Vidal E, Cantarell C, Capdevila L, et al. Mycophenolate mofetil pharmaco-kinetics in transplant patients receiving cyclosporine or tacrolimus in combination therapy. Pharmacol Toxicol 2000 Oct; 87 (4): 182-4
7. Ensom MH, Partovi N, Decarie D, et al. Mycophenolate pharmacokinetics inearly period following lung or heart transplantation. Ann Pharmacother 2003 Dec; 37 (12): 1761-7
8. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report - 2007. J Heart Lung Transplant 2007 Aug; 26 (8): 769-81
9. Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report - 2007. J Heart Lung Transplant 2007 Aug; 26 (8): 782-95
10. Aurora P, Bouček MM, Christie J, et al. Registry of the International Society for Heart and Lung Transplantation: tenth official pediatric lung and heart/lung transplantation report - 2007. J Heart Lung Transplant 2007 Dec; 26 (12): 1223-8
11. Kaufman D, Shapiro RLM!, Cherikh W, et al. Immunosuppression: practice and trends. Am J Transplant 2004; 4 Suppl. 9: 38-53
12. Pou L, Brunet M, Cantarell C, et al. Mycophenolic acid plasma con-centrations: influence of comedication. Ther Drug Monit 2001 Feb; 23 (1): 35-8
13. Galiwango PJ, Delgado DH, Yan R, et al. Mycophenolate mofetil dose reduction for gastrointestinal intolerance is associated with increased rates
14. of rejection in heart transplant patients. J Heart Lung Transplant 2008 Jan; 27(1): 72-7
15. Eisen HJ, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005 May; 24 (5): 517-25
16. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998 Aug 27; 66 (4): 507-15
17. Meiser BM, Pfeiffer M, Schmidt D, et al. Combination therapy with tacro-limus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999 Feb; 18 (2): 143-9
18. Cantarovich M, Giannetti N, Cecere R, et al. Time points predictors of cy-closporine microemulsion and of mycophenolic acid area-under-the-curve (0-12 hr) in long-term heart transplant patients [abstract no. 66]. Am J Transplant 2003 May; 3 (S5): 168
19. Ting LS, Partovi N, Levy RD, et al. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and acyl glucuronide metabolites in stable thoracic transplant recipients. Ther Drug Monit 2008 Jun; 30 (3): 282-91
20. Devyatko E, Ploner M, Zuckermann A, et al. Value of mycophenolic acid trough level monitoring after lung transplantation. Transplant Proc 2002 Aug; 34 (5): 1881-3
21. Knoop C, Haverich A, Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Respir J 2004 Jan; 23 (1): 159-71
22. Snell GI, Westall GP. Immunosuppression for lung transplantation: evidence to date. Drugs 2007; 67 (11): 1531-9
23. Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002 Mar; 24 (3): 330-50
24. DeNofrio D, Loh E, Kao A, et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant 2000 Nov; 19 (11): 1071-6
25. Shaw LM, Korecka M, DeNofrio D, et al. Pharmacokinetic, pharmaco-dynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem 2001 Feb; 34 (1): 17-22
26. Dosch AO, Ehlermann P, Koch A, et al. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. Clin Ther 2006 Jun; 28 (6): 893-905
27. Mardigyan V, Giannetti N, Cecere R, et al. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus. J Heart Lung Transplant 2005 Oct; 24 (10): 1614-8
28. Gajarski RJ, Crowley DC, Zamberlan MC, et al. Lack of correlation between mycophenolate mofetil dose and MPA level in pediatric and young adult cardiac transplant patients: does the MPA level matter? Am J Transplant 2004 Sep; 4 (9): 1495-500
29. Ting LS, Partovi N, Levy RD, et al. Limited sampling strategy for predicting area under the concentration-time curve of mycophenolic acid in adult lung transplant recipients. Pharmacotherapy 2006 Sep; 26 (9): 1232-40
30. Yamani MH, Starling RC, Goormastic M, et al. The impact of routine my-cophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. Transplantation 2000 Jun 15; 69 (11): 2326-30
31. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of myco-phenolate mofetil. Clin Pharmacokinet 1998 Jun; 34 (6): 429-55
32. Premaud A, Debord J, Rousseau A, et al. A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet 2005; 44 (8): 837-47
33. Gerbase MW, Fathi M, Spiliopoulos A, et al. Pharmacokinetics of myco-phenolic acid associated with calcineurin inhibitors: long-term monitoring in stable lung recipients with and without cystic fibrosis. J Heart Lung Transplant 2003 May; 22 (5): 587-90
34. Cussonneau X, Bolon-Larger M, Prunet-Spano C, et al. Relationship between MPA free fraction and free MPAG concentrations in heart transplant recipients based on simultaneous HPLC quantification of the target compounds in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007 Jun 1; 852 (1-2): 674-8
35. Picard N, Ratanasavanh D, Premaud A, et al. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 2005 Jan; 33 (1): 139-46
36. Shipkova M, Armstrong VW, Wieland E, et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 1999 Mar; 126 (5): 1075-82
37. Shipkova M, Strassburg CP, Braun F, et al. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 2001 Mar; 132 (5): 1027-34
38. Picard N, Cresteil T, Premaud A, et al. Characterization of a phase 1 meta-bolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit 2004 Dec; 26 (6): 600-8
39. Schutz E, Shipkova M, Armstrong VW, et al. Identification of a pharmaco-logically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem 1999 Mar; 45 (3): 419-22
40. Briffa N, Morris RE. New immunosuppressive regimens in lung transplan-tation. Eur Respir J 1997 Nov; 10 (11): 2630-7
41. Mandla R, Line PD, Midtvedt K, et al. Automated determination, of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. Ther Drug Monit 2003 Jun; 25 (3): 407-14
42. Gensburger O, Picard N, Marquet P. Effect of mycophenolate acyl-glucuronide on human recombinant type 2 inosine monophosphate dehydrogenase. Clin Chem 2009 May; 55 (5): 986-93
43. Shipkova M, Armstrong VW, Weber L, et al. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 2002 Jun; 24 (3): 390-9
44. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997 Sep; 5 (3): 225-32
45. Meiser BM., Groetzner J, Kaczmarek I, et al. Tacrolimus or cyclosporins: which is the better partner for mycophenolate mofetil in heart transplant recipients? Transplantation 2004 Aug 27; 78 (4): 591-8
46. Groetzner J, Meiser B, Schirmer J, et al. Tacrolimus/mycophenolate mofetil versus cyclosporine/mycophenolate mofetil: comparison of mycophenolate acid trough levels and coronary vasomotor function. J Heart Lung Transplant 2001 Feb; 20 (2): 191
47. Zucker K, Tsaroucha A, Olson L, et al. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999 Feb; 21 (1): 35-43
48. Smak Gregoor PJ, van Gelder T, Hesse CJ, et al. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol. Dial Transplant 1999 Mar; 14 (3): 706-8
49. van Gelder T, Klupp J, Barten. MJ, et al. Comparison of the effects of ta-crolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drag Monit 2001 Apr; 23 (2): 119-28
50. Cattaneo D, Perico N, Gaspari. F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002 Sep; 62 (3): 1060-7
51. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med 2003 Sep 18; 349 (12): 1157-67
52. Bartelink IH, Rademaker CM, Schobben AF, et al. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006; 45 (11): 1077-97
53. Filler G, Drick-Peart J, Christians U. Pharmacokinetics of mycophenolate mofetil and sirolimus in children. Ther Drug Monit 2008 Apr; 30 (2): .138-42
54. Dipchand AI, Pietra B, McCrindle BW, et al. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil. J Heart Lung Transplant 2001 Oct; 20 (10): 1035-43
55. Ting LS, Partovi N, Levy RD, et al. Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients. Ann Pharmacother 2006 Sep; 40 (9): 1509-16
56. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical, practice? A systematic review. Transplantation 2008 Jun 27; 85 (12): 1675-85
57. Cantin B, Giannetti N, Parekh H, et al. Mycophenolic acid concentrations in long-term heart transplant patients: relationship with calcineurin antagonists and acute rejection. Clin Transplant 2002 Jun; 16 (3): 196-201
58. Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007 Nov; 7 (11): 2496-503
59. Kuypers DR, de Jonge H, Naesens M, et al. Current target ranges of myco-phenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 2008 Apr; 30 (4): 673-83
60. Meiser BM, Pfeiffer M, Schmidt D, et al. The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels. Transplant Proc 1999 Feb; 31 (1-2): 84-7
61. van Gelder T, Hilbrands LB, Vaurenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999 Jul 27; 68 (2): 261-6
62. Kaczmarek I, Bigdeli AK, Vogeser M, et al. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients. Ther Drug Monit 2008 Aug; 30 (4): 419-27
63. Premaud A, Le Meur Y, Debord J, et al. Maximum a posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit 2005 Jun; 27 (3): 354-61
64. Le Guellec C, Bourgoin H, Buchler M, et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. Clin Pharmacokinet 2004; 43 (4): 253-66
65. Hesse CJ, Vantrimpont P, van Riemsdijk-van Overbeeke IC, et al. The value of routine monitoring of mycophenolic acid plasma levels after clinical heart transplantation. Transplant Proc 2001 May; 33 (3): 2163-4
66. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998 Dec; 64 (6): 672-83
67. Shipkova M, Beck H, Voland A, et al. Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. Proteomics 2004 Sep; 4 (9): 2728-38
68. Shipkova M, Wieland E, Schutz E, et al. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc 2001 Feb; 33 (1-2): 1080-1
69. Kuypers DR, Claes K, Evenepoel P, et al. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 2004 May; 75 (5): 434-47
70. Zuckermann A, Klepetko W. Use of cyclosporin in thoracic transplantation. Transplant Proc 2004 Mar; 36 (2 Suppl.): 331-6S
71. Poirier CD. Promise of Neoral C2, basiliximab, and everolimus in lung transplantation. Transplant Proc 2004 Mar; 36 (2 Suppl.): 509-.13S
72. Stenton SB, Partovi N, Ensom MH. Sirolimus: the evidence for clinical pharmacokinetic monitoring. Clin Pharmacokinet 2005; 44 (8): 769-86
73. McWilliams TJ, Levvey BJ, Russell PA, et al. Interstitial pneumonitis asso-ciated with sirolimus: a dilemma for lung transplantation. J Heart Lung Transplant 2003 Feb; 22 (2): 210-3
74. King-Biggs MB, Dunitz JM, Park SJ, et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003 May 15; 75 (9): 1437-43
75. Zuckermann A, Manito N, Epailly E, et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008 Feb; 27 (2): 141-9
76. Zahir H, Keogh AM, Akhlaghi F. Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids. Ther Drag Monit 2006 Oct; 28 (5): 614-22
77. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001; 40 (8): 573-85
78. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004 Oct 26; 110 (17): 2694-700
79. Zucker MJ, Baran DA, Arroyo LH, et al. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporin and mycophenolate mofetil: a one-year follow-up analysis. Transplant Proc 2005 Jun; 37 (5): 2231-9
80. Groetzner J, Meiser B, Landwehr P, et al. Mycophenolate mofetil and sir-olimus as calcineurin inhibitor-free immunosuppression for late cardiactransplant recipients with chronic renal failure. Transplantation 2004 Feb 27; 77 (4): 568-74
81. Zimmerman JJ, Ferron GM, Lim HK, et al. The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J Clin Pharmacol 1999 Nov; 39 (11): 1155-61
82. Picard N, Djebli N, Sauvage FL, et al. Metabolism of sirolimus in the presence or absence of cyclosporin by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. Drug Metab Dispos 2007 Mar; 35 (3): 350-5
83. Djebli N, Rousseau A, Hoizey G, et al. Sirolimus population pharmacoki-netic/pharmacogenetic analysis and Bayesian modelling in kidney transplant recipients. Clin Pharmacokinet 2006; 45 (11): 1135-48
84. Zimmerman JJ. Exposure-response relationships and drug interactions of sirolimus. AAPS J 2004; 6 (4): e28
85. Mabasa VH, Ensom MH. The role of therapeutic monitoring of everolimus in solid organ transplantation. Ther Drug Monit 2005 Oct; 27 (5): 666-76
86. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003 Aug 28; 349 (9): 847-58
87. Snell GI, Valentine VG, Vitulo P, et al. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant 2006 Jan; 6 (1): 169-77
88. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004; 43 (2): 83-95
89. Kovarik JM, Noe A, Berthier S, et al. Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics. J Clin Pharmacol 2003 Feb; 43 (2): 141-7
90. Kovarik JM, Hsu CH, McMahon L, et al. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 2001 Sep; 70 (3): 247-54
91. Kovarik JM, Eisen H, Dorent R, et al. Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporin exposure. J Heart Lung Transplant 2003 Oct; 22 (10): 1117-25
92. Kovarik JM, Snell GI, Valentine V, et al. Everolimus in pulmonary trans-plantation: pharmacokinetics and exposure-response relationships. J Heart Lung Transplant 2006 Apr; 25 (4): 440-6
93. Brandhorst G, Tenderich G, Zittermann A, et al. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. Ther Drug Monit 2008 Feb; 30 (1): 113-6
94. Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother 2002 Jun; 36 (6): 981-5
95. Van Damme-Lombaerts R, Webb NA, Hoyer PF, et al. Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients. Pediatr Transplant 2002 Apr; 6 (2): 147-52
96. Hoyer PF, Ettenger R, Kovarik JM, et al. Everolimus in pediatric de nova renal transplant patients. Transplantation 2003 Jun 27; 75 (12): 2082-5
97. Doyle RL, Hertz MI, Dunitz JM, et al. RAD in stable lung and heart/lung transplant recipients: safety, tolerability, pharmacokinetics, and impact of cystic fibrosis. J Heart Lung Transplant 2001 Mar; 20 (3): 330-9
98. Zuckermann A. Clinical experience with Certican (everolimus) in main-tenance heart transplant patients at the Medical University of Vienna. J Heart Lung Transplant 2005 Apr; 24 (4 Suppl.): S206-9
99. Starling RC, Hare JM, Hauptman P, et al. Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant 2004 Dec; 4 (12): 2126-31
100. Anglicheau D, Thervet E, Etienne I, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporin pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75 (5): 422-33
101. Anglicheau D, Pallet N, Rabant M, et al. Role of P-glycoprotein in cyclos-porine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 2006 Sep; 70 (6): 1019-25
102. Oellerich M, Armstrong VW. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments. Ther Drug Monit 2006 Dec; 28 (6): 720-5
103. Cole OJ, Shehata M, Rigg KM. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc 1998 Aug; 30 (5): 2200-3
104. Schuurman HJ, Pally C, Weckbecker G, et al. SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant Proc 1999 Feb; 31 (1-2): 1024-5
105. Nishimura T, Faul JL, Berry GJ, et al. 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 2001 Feb; 163 (2): 498-502
106. Vigano M, Tuzcu M, Benza R, et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant 2007 Jun; 26 (6): 584-92
107. Dumont RJ, Ensom MH. Methods for clinical monitoring of cyclosporin in transplant patients. Clin Pharmacokinet 2000 May; 38 (5): 427-47
108. Trull A, Steel L, Sharples L, et al. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients. Ther Drug Monit 1999 Feb; 21 (1): 17-26
109. Nohria A, Ehtisham J, Ramahi TM. Optimum maintenance trough levels of cyclosporine in heart transplant recipients given corticosteroid-free regimen. J Heart Lung Transplant 1998 Sep; 17 (9): 849-53
110. El Gamel A, Keevil B, Rahman A, et al. Cardiac allograft rejection: do trough cyclosporine levels correlate with the grade of histologic rejection? J Heart Lung Transplant 1997 Mar; 16 (3): 268-74
111. Trull A, Hue K, Tan K, et al. Cross-correlation of cyclosporin concentra-tions and biochemical measures of kidney and liver function in heart and heart-lung transplant recipients. Clin Chem 1990 Aug; 36 (8 Pt 1): .1474-8
112. Trull AK, Best NG, Tan KK, et al. Blood cyclosporin concentrations but not doses correlate with acute changes in renal function following heart and heart-lung transplantation. Ther Drug Monit 1992 Aug; 14 (4): 275-80
113. Aumente MD, Arizón JM, Segura J, et al. Relationship between pharmaco-kinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation. Transplant Proc 2005 Nov; 37 (9): 4014-7
114. Monforte V, Bullich S, Pou L, et al. Blood cyclosporin CO and C2 con-centrations and cytomegalovirus infections following lung transplantation. Transplant Proc 2003 Aug; 35 (5): 1992-3
115. Akhlaghi F, Gonzalez L, Trull AK. Association between cyclosporine con-centrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients. J Heart Lung Transplant 2005 Dec; 24 (12): 2120-8
116. Solari SG, Goldberg LR, DeNofrio D, et al. Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. Ther Drug Monit 2005 Aug; 27 (4): 417-21
117. Best NG, Trull AK, Tan KK, et al. Blood cyclosporin concentrations and the short-term risk of lung rejection following heart-lung transplantation. Br J Clin Pharmacol 1992 Dec; 34 (6): 513-20
118. Cantarovich M, Elstein E, de Varennes B, et al. Clinical benefit of Neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation 1999 Dec 27; 68 (12): 1839-42
119. Cantarovich M, Besner JG, Barkun. JS, et al. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant .1998 Jun; .12 (3): 243-9
120. Baraldo M, Francesconi A, Barbone F, et al. C(2) monitoring of cyclosporine in stable heart transplant patients after two daily and three daily doses. Transplant Proc 2002 Dec; 34 (8): 3246-8
121. Caforio AL, Tona F, Piaserico S, et al. C2 is superior to CO as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients. Transpl Int 2005 Jan; 18 ( 1 ): 116-24
122. Delgado DH, Rao V, Hamel. J, et al. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes. J Heart Lung Transplant 2005 Sep; 24 (9): 1343-6
123. Glanville AR, Morton JM, Aboyoun CL, et al. Cyclosporine C2 monitoring improves renal, dysfunction after lung transplantation. J Heart Lung Transplant 2004 Oct; 23 (10): 1170-4
124. Glanville AR, Aboyoun CL, Morton JM, et al. Cyclosporine C2 target levels and acute cellular rejection after lung transplantation. J Heart Lung Transplant 2006 Aug; 25 (8): 928-34
125. Cantarovich M, Giannetti N, Cecere R. Impact of cyclosporin 2-h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti-thymocyte globulin induction. Clin Transplant 2003 Apr; 17 (2): 144-50
126. Mathias HC, Ozalp F, Will MB, et al. A randomized, controlled trial of CO- versus C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients. J Heart Lung Transplant 2005 Dec; 24 (12): 2137-43
127. Cantarovich M, Quantz M, Elstein E, et al. Neoral dose monitoring with cyclosporine 2-hour postdose levels in heart transplant patients
128. receiving anti-thymocyte globulin induction. Transplant Proc 2000 Mar; 32 (2): 446-8
129. Cantarovich M, Giannetti N, Cecere R. Relationship between endo-myocardial biopsy score and cyclosporine 2-h post-dose levels (C) in heart transplant patients receiving anti-thymocyte globulin induction. Clin Transplant 2004 Apr; 18 (2): 148-51
130. Cantarovich M, Ross H, Arizón JM, et al. Benefit of Neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction. Transplantation 2008 Apr 15; 85 (7): 992-9
131. Morton JM, Aboyoun CL, Malouf MA, et al. Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation. J Heart Lung Transplant 2004 Sep; 23 (9): 1035-9
132. Schubert S, Abdul-Khaliq H, Lehmkuhl HB, et al. Advantages of C2 mon-itoring to avoid acute rejection in pediatric heart transplant recipients. J Heart Lung Transplant 2006 Jun; 25 (6): 619-25
133. Cooney GF, Johnston A. Neoral C-2 monitoring in cardiac transplant pa-tients. Transplant Proc 2001 Feb; 33 (1-2): 1572-5
134. Balram C, Sivathasan C, Cheung YB, et al. A limited sampling strategy for the estimation of 12-hour Neoral systemic drug exposure in heart transplant recipients. J Heart Lung Transplant 2002 Sep; 21 (9): 1016-21
135. Monchaud C, Rousseau A, Leger F, et al. Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation. Eur J Clin Pharmacol 2003 Apr; 58 (12): 813-20
136. Rousseau A, Monchaud C, Debord J, et al. Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis. Ther Drug Monit 2003 Feb; 25 (1): 28-35
137. Undre NA, Stevenson PJ. Pharmacokinetics of tacrolimus in heart trans-plantation. Transplant Proc 2002 Aug; 34 (5): 1836-8
138. Wang CH, Ko WJ, Chou NK, et al. Therapeutic drug monitoring of tacro-limus in cardiac transplant recipients: a comparison with cyclosporine Neoral. Transplant Proc 2004 Oct; 36 (8): 2386-7
139. Aumente Rubio MD, Arizón del Prado JM, López Malo de Molina MD, et al. Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. Transplant Proc 2003 Aug; 35 (5): 1988-91
140. Sgrosso JL, Araujo GL, Vazquez MC. Tacrolimus pharmacokinetics in heart transplant. Transplant Proc 2002 Feb; 34 (1): 142-3
141. Knoop C, Thiry P, Saint-Marcoux F, et al. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. Am J Transplant 2005 Jun; 5 (6): 1477-82
142. Aidong W, Zhenjie C, Tong L, et al. Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation. Transplant Proc 2004 Oct; 36 (8): 2388-9
143. Saint-Marcoux F, Knoop C, Debord J, et al. Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. Clin Pharmacokinet 2005; 44 (12): 1317-28
144. Etienne I, Toupance O, Thierry A, et al. Benefit of a 50% reduction of cy-closporine exposure in stable kidney transplant recipients treated with mycophenolate mofetil without corticosteroids [abstract no. 232]. The DICAM
145. Randomized Study. Am J Transplant 2007 May; 7 (52): 207
146. Ray JE, Keogh AM, McLachlan AJ. Decision support tool to individualize cyclosporine dose in stable, long-term heart transplant recipients receiving metabolic inhibitors: overcoming limitations of cyclosporine C2 monitoring. J Heart Lung Transplant 2006 Oct; 25 (10): 1223-9
147. Morton JM, Mcwhinney B, Hickman PE, et al. Therapeutic drug monitoring (TDM) of prednisolone in lung transplantation. J Heart Lung Transplant 2001 Feb; 20 (2): 192
148. Majid O, Akhlaghi F, Lee T, et al. Simultaneous determination of plasma prednisolone, prednisone, and Cortisol levels by high-performance liquid chromatography. Ther Drug Monit 2001 Apr; 23 (2): 163-8
149. Glander P, Hambach P, Braun KP, et al. Pre-transplant inosine mono-phosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 2004 Dec; 4 (12): 2045-51
150. Wang J, Yang JW, Zeevi A, et al. IMPDHl gene polymorphisms and association with acute rejection in. renal transplant patients. Clin. Pharmacol Ther 2008 May; 83 (5): 711-7
151. Hoffmann SC, Stanley EM, Darrin CE, et al. Association of cytokine poly-morphic inheritance and in vitro cytokine production in anti-CD3/CD28- stimulated peripheral blood lymphocytes. Transplantation 2001 Oct 27; 72 (8): 1444-50
152. Kutukculer N, Clark K, Rigg KM, et al. The value of posttransplant monitoring of interleukin (IL)-2, IL-3, IL-4, IL-6, IL-8, and soluble CD23 in the plasma of renal, allograft recipients. Transplantation 1995 Feb 15; 59 (3): 333-40